<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20309" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Deferoxamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Velasquez</surname>
            <given-names>James</given-names>
          </name>
          <aff>Wyckoff Heights Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wray</surname>
            <given-names>Anton A.</given-names>
          </name>
          <aff>Wyckoff Heights Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Velasquez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anton Wray declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20309.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Deferoxamine (DFO) is a medication used for iron (approved indication) and aluminum toxicity (off-label). It is in the chelator class of drugs. Deferoxamine chelates non-transferrin bound iron (free iron), iron in transit between transferrin and ferritin (labile chelating iron pool), hemosiderin, and ferritin. This activity will highlight the mechanism of action, adverse reactions, interactions, and other factors such as off-label use, dosing, indications, monitoring, and pharmacokinetics. The information is pertinent for members of interprofessional teams in the treatment of iron toxicity and aluminum toxicity.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of deferoxamine.</p></list-item><list-item><p>Describe the potential adverse effects of deferoxamine.</p></list-item><list-item><p>Review the appropriate monitoring for patients using deferoxamine.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance the use of deferoxamine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20309&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20309">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20309.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Deferoxamine (DFO or DFOA) is FDA approved to treat iron overload, either acute or chronic. The definition of iron overload is serial ferritin levels above 800 to 3000 ng/mL.<xref ref-type="bibr" rid="article-20309.r1">[1]</xref>&#x000a0;The FDA has not approved deferoxamine as first-line therapy for hereditary hemochromatosis unless there is a contraindication to phlebotomy. Clinicians can also use deferoxamine as an off-label treatment for aluminum toxicity in chronic kidney disease (CKD) patients.</p>
        <p>Transfusion-related iron overload occurs in patients that require frequent transfusions throughout their life. These patients include those affected by Thalassemia, Sickle cell disease, myelodysplastic syndromes, ineffective hematopoiesis, and other inherited anemic disorders. In this population, chelation should begin two years after transfusions start, serum ferritin levels greater than 1000 mcg/L, or when liver iron concentration (LIC) is greater than 3 mg Fe/g.<xref ref-type="bibr" rid="article-20309.r2">[2]</xref><xref ref-type="bibr" rid="article-20309.r3">[3]</xref><xref ref-type="bibr" rid="article-20309.r4">[4]</xref>&#x000a0;</p>
        <p>Another indication for iron chelation is a cardiac T2* &#x0003c;20 milliseconds found on cardiac magnetic resonance.<xref ref-type="bibr" rid="article-20309.r2">[2]</xref><xref ref-type="bibr" rid="article-20309.r3">[3]</xref><xref ref-type="bibr" rid="article-20309.r4">[4]</xref>&#x000a0;Cardiac MRIs can measure proton relaxation times (T2*) in the cardiac nuclei. Excess iron within these cells speeds up the rate of proton relaxation. This reduced cardiac T2* time is associated with cardiomyopathy, dramatically increasing mortality.<xref ref-type="bibr" rid="article-20309.r5">[5]</xref>&#x000a0;Chelation therapy improves overall survival in these patients and should not be delayed.<xref ref-type="bibr" rid="article-20309.r6">[6]</xref><xref ref-type="bibr" rid="article-20309.r7">[7]</xref><xref ref-type="bibr" rid="article-20309.r8">[8]</xref></p>
        <p>The use of&#x000a0;deferoxamine in acute ingestion of iron is an indication when patients present with systemic toxicity, hemodynamic instability, lethargy, persistent vomiting, metabolic acidosis, or toxic serum iron levels.<xref ref-type="bibr" rid="article-20309.r9">[9]</xref>&#x000a0;Iron levels &#x0003e;500 mcg/dL are considered hazardous, and chelation should be initiated.<xref ref-type="bibr" rid="article-20309.r10">[10]</xref>&#x000a0;Signs and symptoms of systemic toxicity include coagulopathy, cardiomyopathy, and hepatic and renal failure.<xref ref-type="bibr" rid="article-20309.r11">[11]</xref>&#x000a0;Acute iron toxicity progresses through five clinical stages, with the most deadly consequences occurring within the first four days.<xref ref-type="bibr" rid="article-20309.r10">[10]</xref>&#x000a0;Thus, rapid progression through these stages is another indicator that chelation may be necessary.&#x000a0;</p>
        <p>Aluminum toxicity is an off-label use for deferoxamine chelation therapy. Aluminum toxicity can occur in patients with chronic kidney disease who undergo bladder irrigation with aluminum-containing products, use phosphate binders that contain aluminum, or receive hemodialysis with a water source contaminated with aluminum. Its use is indicated in patients with signs and symptoms associated with chronic aluminum levels greater than &#x0003e;20 mcg/L, such as osteomalacia, anemia, hypercalcemia, and dialysis dementia.<xref ref-type="bibr" rid="article-20309.r12">[12]</xref><xref ref-type="bibr" rid="article-20309.r13">[13]</xref>&#x000a0;It is also an indicated use in acute toxicity, which results from exposure to &#x0003e;200 mcg/L of aluminum resulting in acute encephalopathy.<xref ref-type="bibr" rid="article-20309.r14">[14]</xref></p>
      </sec>
      <sec id="article-20309.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Iron is an essential part of human physiology. It is a vital element in proteins such as hemoglobin, myoglobin, and cytochrome and also functions as a cofactor for many enzymes. It is stored by ferritin and transferred throughout the serum by transferrin. No physiological mechanism exists to excrete iron. Instead, humans regulate GI uptake by altering hepcidin levels.<xref ref-type="bibr" rid="article-20309.r15">[15]</xref>&#x000a0;When iron storing proteins become saturated, free iron species accumulate in the plasma. These include non-transferable bound iron (NTBI) and labile plasma iron (LBI).<xref ref-type="bibr" rid="article-20309.r16">[16]</xref>&#x000a0;</p>
        <p>Cells also take up free iron to form labile iron pools (LIP) within their cell membranes.<xref ref-type="bibr" rid="article-20309.r16">[16]</xref>&#x000a0;This excess iron within cells catalyzes the production of free radicals via the Fenton reaction.<xref ref-type="bibr" rid="article-20309.r17">[17]</xref>&#x000a0;Free radicals lead to DNA destruction and cellular damage. Free iron also precipitates acidosis by inhibiting oxidative phosphorylation in mitochondria.<xref ref-type="bibr" rid="article-20309.r17">[17]</xref>&#x000a0;Deferoxamine is a molecule produced by the fermentation of <italic toggle="yes">Streptomyces pilosus.</italic><xref ref-type="bibr" rid="article-20309.r18">[18]</xref>&#x000a0;It binds free plasma iron and excess iron within cells. deferoxamine is a hexadentate molecule and is able to bind iron at a 1-to-1 ratio.<xref ref-type="bibr" rid="article-20309.r19">[19]</xref>&#x000a0;</p>
        <p>The bound form of deferoxamine is then excreted via the urine or bile.<xref ref-type="bibr" rid="article-20309.r19">[19]</xref>&#x000a0;Deferoxamine&#x000a0;chelates non-transferrin bound iron (free iron), iron in transit between transferrin and ferritin (labile chelating iron pool), hemosiderin, and ferritin. Although deferoxamine can directly bind and remove iron from myocardial cells, it will not bind iron already bound to molecules such as transferrin, hemoglobin, or cytochromes.<xref ref-type="bibr" rid="article-20309.r19">[19]</xref>&#x000a0;Thus, only a small amount of iron is available for chelation at any given time. Although this is a small fraction of total body iron, it has a profound effect. When bound, the resultant ferrioxamine is very water-soluble. If chelation occurs in hepatocytes, the compound will be excreted in bile, and when chelation occurs with free iron in plasma or other tissues, it is excreted by the kidneys.</p>
        <p>Deferoxamine can also bind aluminum within the plasma to form aluminoxane, which is renally excreted. In the case of CKD/ESRD patients, the product is dialyzable using a high-flux membrane.<xref ref-type="bibr" rid="article-20309.r20">[20]</xref>&#x000a0;Deferoxamine&#x000a0;can draw aluminum deposited in tissues into the plasma.<xref ref-type="bibr" rid="article-20309.r20">[20]</xref>&#x000a0;For this reason, patients with a measured serum aluminum concentration &#x0003e;200 mcg/L should not be treated with deferoxamine as it may lead to severely high levels of aluminum and fatal neurotoxicity. The recommended administration will be discussed in the following section. &#x000a0;</p>
      </sec>
      <sec id="article-20309.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Deferoxamine is poorly absorbed from the GI tract when taken orally. For this reason, it must be given intramuscularly, subcutaneously, or intravenously.<xref ref-type="bibr" rid="article-20309.r3">[3]</xref><xref ref-type="bibr" rid="article-20309.r21">[21]</xref>&#x000a0;The subcutaneous route is preferable for those patients with chronic iron overload. Intravenous deferoxamine is reserved for those with acute ingestion and life-threatening symptoms.<xref ref-type="bibr" rid="article-20309.r9">[9]</xref>&#x000a0;Figure 1 summarizes recommended dosages and administration times for deferoxamine in iron toxicity.</p>
        <p>A 25 gauge or smaller butterfly needle is used for the SQ route. The abdomen is generally the safest and most common area to avoid important vessels and nerves. A 10% deferoxamine solution is administered subcutaneously over 8&#x000a0;to 12 hours using a slow infusion pump.<xref ref-type="bibr" rid="article-20309.r22">[22]</xref>&#x000a0;The dose is dependent on the patient's age and weight. Approximately 40 to 60 mg/kg/day is given for 4&#x000a0;to 5 days per week.<xref ref-type="bibr" rid="article-20309.r22">[22]</xref>&#x000a0;The total dose should not exceed 2.5g daily.<xref ref-type="bibr" rid="article-20309.r23">[23]</xref></p>
        <p>Intravenous administration is reserved for those patients with severe acute iron toxicity with Iron levels &#x0003e;500 mcg/dL, severe cardiac disease (dysrhythmias, LV dysfunction, severe heart iron loading (T2*&#x0003c;6 ms on MRI)), or those who cannot tolerate the subcutaneous infusion.<xref ref-type="bibr" rid="article-20309.r10">[10]</xref><xref ref-type="bibr" rid="article-20309.r24">[24]</xref><xref ref-type="bibr" rid="article-20309.r25">[25]</xref>&#x000a0;The standard dose of 50&#x000a0;to 60 mg/kg/day or 5&#x000a0;to 15 mg/kg/h is given as a 24-hour infusion using an indwelling catheter.<xref ref-type="bibr" rid="article-20309.r26">[26]</xref><xref ref-type="bibr" rid="article-20309.r27">[27]</xref>&#x000a0;Patients should not receive deferoxamine for more than 24 hours intravenously as this can increase the risk of developing ARDS and other complications.<xref ref-type="bibr" rid="article-20309.r28">[28]</xref><xref ref-type="bibr" rid="article-20309.r29">[29]</xref></p>
        <p>The dose of deferoxamine may be reduced or increased by using clinical judgment, decreasing liver ion concentrations, or calculating the therapeutic index, which divides the daily dose of deferoxamine by the serum ferritin levels. The therapeutic index should be &#x0003c;.025 at all times to avoid serious adverse effects.<xref ref-type="bibr" rid="article-20309.r30">[30]</xref></p>
        <p>Vitamin C can potentiate the therapeutic effect of deferoxamine by mobilizing iron stores, subsequently increasing the concentration of chelatable iron.<xref ref-type="bibr" rid="article-20309.r5">[5]</xref>&#x000a0;On the other hand, this increase in free iron can potentiate iron toxicity leading to impaired cardiac function and worsening overload. For this reason, the FDA advises that supplemental vitamin C should be avoided in patients with cardiac failure and should only start after an initial one month of standard deferoxamine treatment has been completed. Furthermore, its use is only indicated in those patients receiving regular deferoxamine therapy and should not exceed 200 mg/day. Close evaluation of the patient's cardiac function is of the utmost importance when using this combined therapy.</p>
        <p>In aluminum toxicity, the appropriate dosing and therapy duration of&#x000a0;the drug is uncertain and should be tailored by serum aluminum levels, symptoms, and response. The National Kidney Foundation has listed specific guidelines for the use of deferoxamine in aluminum toxicity, which this article will cover. A proposed mechanism by the Kidney Disease Outcomes Quality Initiative states that in symptomatic patients with serum aluminum levels &#x0003e;60 &#x003bc;g/L but &#x0003c;200 &#x003bc;g/L or a rise in aluminum after DFO &#x0003e;50 &#x003bc;g/L, deferoxamine should be given to treat the aluminum overload. Deferoxamine's ability to draw aluminum out of tissues and into the plasma makes its use very dangerous in those patients with serum aluminum levels &#x0003e;200 &#x003bc;g/L. To avoid DFO-induced neurotoxicity in these patients, its use should delay until the completion of intensive dialysis (6 days per week) with a high-flux dialysis membrane and a dialysate aluminum level of &#x0003c;5 &#x003bc;g/L and until the pre-dialysis serum aluminum level has been reduced to &#x0003c;200 &#x003bc;g/L.</p>
      </sec>
      <sec id="article-20309.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Chronic deferoxamine therapy can lead to sensorineural hearing loss and retinopathy. Though the mechanism of ocular injury is not well understood, it appears to partially occur due to damage to the retinal pigment epithelium, which can lead to decreased visual acuity, visual field defects, and color vision defects.<xref ref-type="bibr" rid="article-20309.r31">[31]</xref>&#x000a0;Hearing and vision loss can be reversible if the patient discontinues&#x000a0;the drug early in the course.<xref ref-type="bibr" rid="article-20309.r23">[23]</xref>&#x000a0;Growth retardation can also occur in children receiving deferoxamine treatment, and clinicians should monitor patients for appropriate growth velocity over time.<xref ref-type="bibr" rid="article-20309.r32">[32]</xref>&#x000a0;</p>
        <p>Administering less than 2.5 g of deferoxamine per day and monitoring the therapeutic index is the best&#x000a0;means to avoid such complications. Acute side effects can include GI complaints, anaphylaxis, skin discoloration, skin irritation, and anaphylaxis. Chelation of iron and formation of the water-soluble compound ferioxamine may lead to rose-colored urine. Deferoxamine&#x000a0;can increase the risk of infection by specific pathogens and invasive fungi such as mucormycosis, <italic toggle="yes">Yersinia</italic>, and<italic toggle="yes"> Vibrio.</italic><xref ref-type="bibr" rid="article-20309.r33">[33]</xref><xref ref-type="bibr" rid="article-20309.r34">[34]</xref>&#x000a0;ARDS is another potential and rare complication that occurs most often when giving the drug via intravenous infusion for more than 24 hours.<xref ref-type="bibr" rid="article-20309.r28">[28]</xref><xref ref-type="bibr" rid="article-20309.r29">[29]</xref></p>
      </sec>
      <sec id="article-20309.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Deferoxamine is relatively safe and well-tolerated by patients. Its use is contraindicated in patients with previous hypersensitivity reactions to the drug and those with renal disease or anuria. Deferoxamine&#x000a0;is a pregnancy category C drug and is usually reserved for women at high risk of cardiac disease or severe symptoms from acute ingestion. Although there is no evidence to indicate that&#x000a0;the drug is a teratogen, animal studies have shown adverse fetal effects. Clinicians should be cautious in using during pregnancy, and the risks vs. benefits must merit consideration in each case. It is unknown if deferoxamine is excreted in breast milk.&#x000a0;</p>
      </sec>
      <sec id="article-20309.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The therapeutic index is a crucial measurement for deferoxamine therapy, and the provider should calculate it regularly. It can be calculated by dividing the mean daily dose over seven days by the measured ferritin levels.<xref ref-type="bibr" rid="article-20309.r30">[30]</xref>&#x000a0;Complication risk can be mitigated while using deferoxamine by keeping the therapeutic index below 0.025,&#x000a0;and the patient's daily dose requires adjustment for the alternating ferritin levels.<xref ref-type="bibr" rid="article-20309.r30">[30]</xref> Besides monitoring the patient's iron stores, regular screening for adverse effects is also advisable. A screening hearing exam should be performed in the clinic every six months and a formal audiogram every 12 months.<xref ref-type="bibr" rid="article-20309.r23">[23]</xref>&#x000a0;</p>
        <p>An evaluation by an ophthalmologist should take place in children every six months and annually in adults. Since the kidneys excrete most of the chelation byproduct ferrioxamine, it is essential to monitor the patient's renal function. The patient's chemistry, BUN/Cr, and urine protein/Cr ratios should be measured at least four times a year, and the clinicians should reduce the deferoxamine dose with worsening renal function.&#x000a0;</p>
      </sec>
      <sec id="article-20309.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Patients tolerate deferoxamine well, and there is no specific antidote for the medication. The precautions and dose reductions are described elsewhere in this paper.&#x000a0;</p>
      </sec>
      <sec id="article-20309.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Deferoxamine treatment can be a tedious and painful process, with common local skin reactions. The patient will require strong supportive relationships with several providers, nurses, and family to maximize compliance. To provide safe chelation therapy, a patient must comply with their primary care doctor, ophthalmologist, endocrinologist, nephrologist, and hematologist. These interprofessional teams are vital to successful outcomes that decrease mortality and complications. Many of those who require chelation begin at a young age due to hereditary disease. Compliance in this age group is usually high compared to others due to parental support.<xref ref-type="bibr" rid="article-20309.r35">[35]</xref>&#x000a0;</p>
        <p>Compliance with the strict regimen can become problematic in adolescence or when life burdens become too cumbersome for a patient to manage. One multicenter study in Germany found that patients had more misery from chelation treatment than the disease requiring it.<xref ref-type="bibr" rid="article-20309.r35">[35]</xref>&#x000a0;</p>
        <p>Patient involvement, education, and behavioral support are of utmost importance. A systematic review from the Agency for Healthcare Research and Quality on interventions to improve adherence to self-administered medications found that reduced out-of-pocket expenses, case management, and patient education with behavioral support improved medication adherence.<xref ref-type="bibr" rid="article-20309.r36">[36]</xref>&#x000a0;Shared decision-making also has an important role. There are a variety of chelators available for Iron overdose, and providers should seek the option with the lowest burden to the patient. Allowing patients to change the chelator for various reasons helped increase compliance with the regimen.<xref ref-type="bibr" rid="article-20309.r37">[37]</xref>&#x000a0;We must remember that chelation will be a life-long therapy for most of these patients. It is thus critical for providers to be empathetic, educational, and inspiring.</p>
      </sec>
      <sec id="article-20309.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20309&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20309">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20309/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20309">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20309.s11">
        <fig id="article-20309.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Deferoxamine Doses Contributed by James Velasquez, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__1__DFO__Dosages" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20309.s12">
        <title>References</title>
        <ref id="article-20309.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballas</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Zeidan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Duong</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>DeVeaux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heeney</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>The effect of iron chelation therapy on overall survival in sickle cell disease and &#x003b2;-thalassemia: A systematic review.</article-title>
            <source>Am J Hematol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>943</fpage>
            <page-range>943-952</page-range>
            <pub-id pub-id-type="pmid">29635754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aydinok</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kattamis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viprakasit</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Current approach to iron chelation in children.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>165</volume>
            <issue>6</issue>
            <fpage>745</fpage>
            <page-range>745-55</page-range>
            <pub-id pub-id-type="pmid">24646011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olivieri</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Brittenham</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Iron-chelating therapy and the treatment of thalassemia.</article-title>
            <source>Blood</source>
            <year>1997</year>
            <month>Feb</month>
            <day>01</day>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>739</fpage>
            <page-range>739-61</page-range>
            <pub-id pub-id-type="pmid">9028304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggio</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Light and shadows in the iron chelation treatment of haematological diseases.</article-title>
            <source>Br J Haematol</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>138</volume>
            <issue>4</issue>
            <fpage>407</fpage>
            <page-range>407-21</page-range>
            <pub-id pub-id-type="pmid">17659052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart.</article-title>
            <source>Quant Imaging Med Surg</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>407</fpage>
            <page-range>407-12</page-range>
            <pub-id pub-id-type="pmid">25392825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Darlison</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.</article-title>
            <source>Lancet</source>
            <year>2000</year>
            <month>Jun</month>
            <day>10</day>
            <volume>355</volume>
            <issue>9220</issue>
            <fpage>2051</fpage>
            <page-range>2051-2</page-range>
            <pub-id pub-id-type="pmid">10885361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delea</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Edelsberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sofrygin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Baladi</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Phatak</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.</article-title>
            <source>Transfusion</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1919</fpage>
            <page-range>1919-29</page-range>
            <pub-id pub-id-type="pmid">17880620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borgna-Pignatti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rugolotto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Romeo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Forni</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Gamberini</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ghilardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Piga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cnaan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.</article-title>
            <source>Haematologica</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>89</volume>
            <issue>10</issue>
            <fpage>1187</fpage>
            <page-range>1187-93</page-range>
            <pub-id pub-id-type="pmid">15477202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madiwale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liebelt</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Iron: not a benign therapeutic drug.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-9</page-range>
            <pub-id pub-id-type="pmid">16601499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Oderda</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Favin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Assessment of management guidelines. Acute iron ingestion.</article-title>
            <source>Clin Pediatr (Phila)</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>316</fpage>
            <page-range>316-21</page-range>
            <pub-id pub-id-type="pmid">2361339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mills</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Acute iron poisoning.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>1994</year>
            <month>May</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>397</fpage>
            <page-range>397-413</page-range>
            <pub-id pub-id-type="pmid">8187690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delmez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Slatopolsky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1992</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>303</fpage>
            <page-range>303-17</page-range>
            <pub-id pub-id-type="pmid">1562018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bansal</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nervous system disorders in dialysis patients.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2014</year>
            <volume>119</volume>
            <fpage>395</fpage>
            <page-range>395-404</page-range>
            <pub-id pub-id-type="pmid">24365308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berend</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van der Voet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boer</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe.</article-title>
            <source>Kidney Int</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>746</fpage>
            <page-range>746-53</page-range>
            <pub-id pub-id-type="pmid">11168958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Origa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galanello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Giagu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maccioni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Faa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nemeth</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Liver iron concentrations and urinary hepcidin in beta-thalassemia.</article-title>
            <source>Haematologica</source>
            <year>2007</year>
            <month>May</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>583</fpage>
            <page-range>583-8</page-range>
            <pub-id pub-id-type="pmid">17488680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Ponka</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Iron overload in human disease.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jan</month>
            <day>26</day>
            <volume>366</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-59</page-range>
            <pub-id pub-id-type="pmid">22276824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hebbel</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes.</article-title>
            <source>Clin Haematol</source>
            <year>1985</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-40</page-range>
            <pub-id pub-id-type="pmid">2985310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barona-G&#x000f3;mez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Giannakopulos</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Derrick</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Challis</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Identification of a cluster of genes that directs desferrioxamine biosynthesis in Streptomyces coelicolor M145.</article-title>
            <source>J Am Chem Soc</source>
            <year>2004</year>
            <month>Dec</month>
            <day>22</day>
            <volume>126</volume>
            <issue>50</issue>
            <fpage>16282</fpage>
            <page-range>16282-3</page-range>
            <pub-id pub-id-type="pmid">15600304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hershko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Konijn</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nick</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Breuer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cabantchik</surname>
                <given-names>ZI</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.</article-title>
            <source>Blood</source>
            <year>2001</year>
            <month>Feb</month>
            <day>15</day>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>1115</fpage>
            <page-range>1115-22</page-range>
            <pub-id pub-id-type="pmid">11159545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molitoris</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Alfrey</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Alfrey</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.</article-title>
            <source>Kidney Int</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-101</page-range>
            <pub-id pub-id-type="pmid">3172641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beris</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Introduction: management of thalassemia.</article-title>
            <source>Semin Hematol</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <pub-id pub-id-type="pmid">8560281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Overcoming the challenge of patient compliance with iron chelation therapy.</article-title>
            <source>Semin Hematol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>2 Suppl 1</issue>
            <fpage>S19</fpage>
            <page-range>S19-21</page-range>
            <pub-id pub-id-type="pmid">15846581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olivieri</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Buncic</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gallant</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skarf</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.</article-title>
            <source>N Engl J Med</source>
            <year>1986</year>
            <month>Apr</month>
            <day>03</day>
            <volume>314</volume>
            <issue>14</issue>
            <fpage>869</fpage>
            <page-range>869-73</page-range>
            <pub-id pub-id-type="pmid">3485251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Abeysinghe</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hider</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.</article-title>
            <source>Blood</source>
            <year>1996</year>
            <month>Jul</month>
            <day>15</day>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>705</fpage>
            <page-range>705-13</page-range>
            <pub-id pub-id-type="pmid">8695819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westwood</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Maceira</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wonke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pennell</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron.</article-title>
            <source>J Magn Reson Imaging</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>1147</fpage>
            <page-range>1147-51</page-range>
            <pub-id pub-id-type="pmid">17520718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jarritt</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Jul</month>
            <day>01</day>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>263</fpage>
            <page-range>263-9</page-range>
            <pub-id pub-id-type="pmid">15001468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.</article-title>
            <source>Blood</source>
            <year>2000</year>
            <month>Feb</month>
            <day>15</day>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>1229</fpage>
            <page-range>1229-36</page-range>
            <pub-id pub-id-type="pmid">10666195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannides</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Panisello</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Acute respiratory distress syndrome in children with acute iron poisoning: the role of intravenous desferrioxamine.</article-title>
            <source>Eur J Pediatr</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>159</volume>
            <issue>3</issue>
            <fpage>158</fpage>
            <page-range>158-9</page-range>
            <pub-id pub-id-type="pmid">10664227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenenbein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sienko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bowden</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>IY</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning.</article-title>
            <source>Lancet</source>
            <year>1992</year>
            <month>Mar</month>
            <day>21</day>
            <volume>339</volume>
            <issue>8795</issue>
            <fpage>699</fpage>
            <page-range>699-701</page-range>
            <pub-id pub-id-type="pmid">1347583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jaswon</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Huehns</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>East</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hazell</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.</article-title>
            <source>Br J Haematol</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-9</page-range>
            <pub-id pub-id-type="pmid">2605127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Athanasiov</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gilhotra</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Desferrioxamine-related ocular toxicity: a case report.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-7</page-range>
            <pub-id pub-id-type="pmid">22824603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Virgiliis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Congia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Argiolu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diana</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cucca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Varsi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Podda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fodde</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Deferoxamine-induced growth retardation in patients with thalassemia major.</article-title>
            <source>J Pediatr</source>
            <year>1988</year>
            <month>Oct</month>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>661</fpage>
            <page-range>661-9</page-range>
            <pub-id pub-id-type="pmid">3171791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boelaert</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>de Locht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kerrels</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cantinieaux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verdonck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Landuyt</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.</article-title>
            <source>J Clin Invest</source>
            <year>1993</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>1979</fpage>
            <page-range>1979-86</page-range>
            <pub-id pub-id-type="pmid">8486769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>1992</year>
            <season>Jul-Sep</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-54</page-range>
            <pub-id pub-id-type="pmid">1525003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldbeck</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baving</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohne</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Psychosocial aspects of beta-thalassemia: distress, coping and adherence].</article-title>
            <source>Klin Padiatr</source>
            <year>2000</year>
            <season>Sep-Oct</season>
            <volume>212</volume>
            <issue>5</issue>
            <fpage>254</fpage>
            <page-range>254-9</page-range>
            <pub-id pub-id-type="pmid">11048284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Golin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Ashok</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blalock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wines</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Coker-Schwimmer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Sista</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lohr</surname>
                <given-names>KN</given-names>
              </name>
            </person-group>
            <article-title>Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review.</article-title>
            <source>Ann Intern Med</source>
            <year>2012</year>
            <month>Dec</month>
            <day>04</day>
            <volume>157</volume>
            <issue>11</issue>
            <fpage>785</fpage>
            <page-range>785-95</page-range>
            <pub-id pub-id-type="pmid">22964778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20309.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trachtenberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vichinsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haines</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pakbaz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mednick</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sobota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Giardina</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Neufeld</surname>
                <given-names>EJ</given-names>
              </name>
              <collab>Thalassemia Clinical Research Network</collab>
            </person-group>
            <article-title>Iron chelation adherence to deferoxamine and deferasirox in thalassemia.</article-title>
            <source>Am J Hematol</source>
            <year>2011</year>
            <month>May</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>433</fpage>
            <page-range>433-6</page-range>
            <pub-id pub-id-type="pmid">21523808</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
